Education
MS, Pathology and Molecular Medicine, Queen’s UniversityMD, Medicine, University College Dublin, National University of Ireland
Fellow, Movement Disorders - Experimental Therapeutics, University of Rochester Medical Center
Publications
Killoran, A. (2017). The Clinical Features of Huntington's Disease. In C. Hughes (Eds.) Huntington's Disease: Prevalence, Pathogenesis and Treatment. Nova Science Publishers.
Killoran, A., Biglan, K. (2016). Biomarkers for Huntington’s disease: a brief overview. Journal of Rare Disease Research & Treatment., 1(2), 46-50.
Killoran, A., Biglan, K. M. (2014). Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?. Movement disorders : official journal of the Movement Disorder Society, 29(11), 1404-13. PMID: 25164707.
Killoran, A., Biglan, K. M. (2014). Movement, Facial. In D. Weisbrot , A. Ettinger (Eds.) Neurological Differential Diagnosis: A Case-based Approach. pp. 247-249. Cambridge University Press. PMID: 1107014557.
Killoran, A., Biglan, K. M., Jankovic, J., Eberly, S., Kayson, E., Oakes, D., Young, A. B. & Shoulson, I. (2013). Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology, 80(22), 2022-7. PMID: 23624566.
Abdolahi, A., Scoglio, N., Killoran, A., Dorsey, E. R. & Biglan, K. M. (2013). Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Parkinsonism & related disorders, 19(2), 218-21. PMID: 23102808.
Biglan, K. M., Zhang, Y., Long, J. D., Geschwind, M., Kang, G. A., Killoran, A., Lu, W., McCusker, E., Mills, J. A., Raymond, L. A., Testa, C., Wojcieszek, J. & Paulsen, J. S. (2013). Refining the diagnosis of Huntington disease: the PREDICT-HD study. Frontiers in aging neuroscience, 5, 12. PMID: 23565093.
Killoran, A., Biglan, K. M. (2012). 8-OHdG: its (limited) potential as a biomarker for Huntington's disease. (Vols. 6). (6), pp. 777-80. Biomarkers in medicine. PMID: 23227841.
Killoran, A. (2012). Ask the Experts. Neurology Now, 8(2), 35. DOI: 10.1097/01.nnn.0000414219.75201.0b.
Killoran, A., Biglan, K. M. (2012). Therapeutics in Huntington's Disease. Current treatment options in neurology. PMID: 22314929.
Killoran, A., Marshall, F. (In Press). Parkinsonian Syndromes: Co 1 tricobasal degeneration. In S. Gilman , J. Markovac (Eds.) Neurobiology of disease. (2nd ed.) Oxford University Press.
Thompson, M. D., Killoran, A., Percy, M. E., Nezarati, M., Cole, D. E. & Hwang, P. A. (2006). Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder?. Pediatric neurology, 34(4), 303-7. PMID: 16638507.
Bouwman, C. W., Kohli, M., Killoran, A., Touchie, G. A., Kadner, R. J. & Martin, N. L. (2003). Characterization of SrgA, a Salmonella enterica serovar Typhimurium virulence plasmid-encoded paralogue of the disulfide oxidoreductase DsbA, essential for biogenesis of plasmid-encoded fimbriae. Journal of bacteriology, 185(3), 991-1000. PMID: 12533475.
Notley, C., Killoran, A., Cameron, C., Wynd, K., Hough, C. & Lillicrap, D. (2002). The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Human gene therapy, 13(13), 1583-93. PMID: 12228013.